Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most

Jun 11 2018

• By Mandy Jackson

Human brain illustrated with millions of small nerves - Conceptual 3d render

Related Content

Response Rates Rule In CGRP Inhibitor Migraine Studies

Jun 12 2017

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

May 09 2017

Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

Apr 28 2018

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

May 15 2018

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Mar 15 2018

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

Aug 01 2011

Allergan migraine portfolio grows with Merck CGRP antagonists

Jul 08 2015

Which Biotechs Enjoyed A 'JPM Jump' - And Which Lost Out?

Jan 22 2018

Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

Feb 06 2018

Activist Investors Seek Action At Allergan, But Are They Aligned?

Jun 07 2018

Teva Pushes CGRP Timeline Back To End Of 2018

May 03 2018

ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price

Jun 02 2018

Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead

Jun 01 2018

Related Companies

Allergan plc

Merck & Co., Inc.

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Celltrion, Inc.

Alder Biopharmaceuticals, Inc.

Biohaven Pharmaceutical Holding Company Ltd.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials Companies Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window